Replies to post #177274 on Biotech Values

[DewDiligence]

PlantForm, PharmaPraxis ink FoB collaboration for Brazilian market:

http://t.co/RyO9nD8pZG

PlantForm Corporation of Canada and PharmaPraxis of Brazil are pleased to announce the establishment of a joint venture to develop, manufacture and commercialize biosimilar and/or biobetter versions of six key biopharmaceuticals for the Brazilian market, using PlantForm’s low-cost manufacturing system.

The joint venture will first develop a biosimilar/biobetter version of the oncology drug Avastin (bevacizumab), in collaboration with the Fraunhofer Center for Molecular Biology in Newark, Delaware, USA, which will produce the active pharmaceutical ingredient for clinical trials.

Brazilian government corporation Bio-Manguinhos will also participate in the project. Bio- Manguinhos is responsible for technology development and production of vaccines, reagents and biopharmaceuticals to meet public health demands.

These companies are not exactly household names, but there is money to be made by somebody selling FoBs in Brazil.

[DewDiligence]

Announced FoB Collaborations

[Added entry for Plantform-PharmaPraxis.]


Items are shown in reverse chronological order. This table does not purport to be exhaustive.

 
                     Date   Targets   Geography     iHub References 
 PlantForm-PhrmaPrxs 6/14   Avastin+  Brazil        #msg-103576633 
 Lupin-Yoshindo      4/14   Enbrel+   Japan         #msg-101018361 
 BAX-Coherus         9/13   Enbrel    ex-US         #msg-91645674 
 Oncobiolgcs-Huahai  5/13   #         global        #msg-87734336,#msg-87744882 
 Strides-Pfenex      4/13   Betaseron global        #msg-87014470 
 MRK-Samsng/BIIB     2/13   @         Europe+       #msg-84781042,#msg-69629103,#msg-95065880 
 Catalent-UMN       12/12   various   Asia          #msg-82556713 
 Merck KGaA-RDY      6/12   oncology  global        #msg-76359649 
 Daiichi-Coherus     5/12   *         Asia          #msg-75397629 
 Fujifilm-Kyowa      3/12   Humira    unspecified   #msg-73800486 
 ACT-Bioton          2/12   insulin   US & Europe   #msg-74987123 
 ACT-AMGN           12/11   †         global        #msg-70097496,#msg-84340328 
 BAX-MNTA           12/11   ‡         global        #msg-70212854,#msg-70258421 
 HSP-Celltrion      10/09   z         global        #msg-84519981,#msg-77816122 
 MYL-Biocon          6/09   x         global        #msg-72421544,#msg-84561737 
 Procognia-UTR       n/a    Humira    unspecified   #msg-84340976 

*Enbrel and Rituxan.

†Humira, Remicade, Herceptin, Avastin, Rituxan, Erbitux; excludes AMGN FoB’s for AMGN’s branded drugs.

‡Three products in development: 2 auto-immune and 1 oncology—my guesses are Humira, Orenica, Erbitux; may include up to 6 products eventually.

@ Samsung/BIIB subordinate collaboration known as Samsung Bioepis developing Remicade and Enbrel FoB’s in Europe (#msg-95065880); Rituxan program terminated (#msg-80622249).

#Humira, Rituxan, Avastin, Herceptin.

x Nine products: Herceptin, Neulasta, Avastin, Humira, Enbrel, Lantus, Novolog, Humalog, one undisclosed.

y Rituxan program terminated (#msg-80236315); status of other programs unknown.

z Each company received a distinct EU/CHMP approval for Remicade on 6/28/13; partnership includes seven (other) products: Rituxan, Herceptin, Enbrel, Erbitux, Synagis, Humira, Avastin.